Mitsubishi UFJ Asset Management Portfolio holdings
AUM
$125B
1-Year Return
23.89%
This Quarter Return
-14.8%
1 Year Return
+23.89%
3 Year Return
+93.04%
5 Year Return
+163.06%
10 Year Return
+400.91%
AUM
$22.6B
AUM Growth
-$2.7B
(-11%)
Cap. Flow
+$1.53B
Cap. Flow
% of AUM
6.76%
Top 10 Holdings %
Top 10 Hldgs %
24.02%
Holding
1,238
New
87
Increased
775
Reduced
172
Closed
95
Top Buys
| 1 |
Apple
AAPL
|
$90.9M |
| 2 |
Microsoft
MSFT
|
$82.2M |
| 3 |
Amazon
AMZN
|
$46.5M |
| 4 |
Amgen
AMGN
|
$37.6M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$30.1M |
Top Sells
| 1 |
Vanguard S&P 500 ETF
VOO
|
$23.9M |
| 2 |
AT&T
T
|
$18.4M |
| 3 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
$16.7M |
| 4 |
Baidu
BIDU
|
$14.8M |
| 5 |
CERN
Cerner Corp
CERN
|
$14.2M |
Sector Composition
| 1 | Technology | 24.32% |
| 2 | Healthcare | 14.31% |
| 3 | Financials | 11.76% |
| 4 | Consumer Discretionary | 10.46% |
| 5 | Communication Services | 7.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Blue Bird Corp
BLBD
$1.87B
| $284K | ﹤0.01% |
30,878
-5,667
| -16% | -$52.1K |
|
1002
Avidity Biosciences
RNA
$6.48B
| $284K | ﹤0.01% |
+19,555
| New | +$284K |
|
1003
Xencor
XNCR
$610M
| $284K | ﹤0.01% |
10,392
+2,214
| +27% | +$60.5K |
|
|
LAND
1004
Gladstone Land Corp
LAND
$325M
| $283K | ﹤0.01% |
12,774
| – | – |
|
|
CYBE
1005
DELISTED
Cyberoptics Corp
CYBE
| $281K | ﹤0.01% |
8,041
+1,666
| +26% | +$58.2K |
|
1006
Accuray
ARAY
$170M
| $274K | ﹤0.01% |
139,560
+11,585
| +9% | +$22.7K |
|
1007
Fate Therapeutics
FATE
$116M
| $274K | ﹤0.01% |
11,071
+5,511
| +99% | +$136K |
|
|
UHT
1008
Universal Health Realty Income Trust
UHT
$574M
| $274K | ﹤0.01% |
5,156
| – | – |
|
|
RMO
1009
DELISTED
Romeo Power, Inc.
RMO
| $269K | ﹤0.01% |
600,576
+355,855
| +145% | +$159K |
|
1010
Editas Medicine
EDIT
$248M
| $268K | ﹤0.01% |
22,660
+13,721
| +153% | +$162K |
|
1011
Sarepta Therapeutics
SRPT
$1.96B
| $268K | ﹤0.01% |
3,580
-356
| -9% | -$26.7K |
|
1012
CRISPR Therapeutics
CRSP
$4.99B
| $266K | ﹤0.01% |
4,376
+609
| +16% | +$37K |
|
1013
Sangamo Therapeutics
SGMO
$165M
| $260K | ﹤0.01% |
62,874
+29,131
| +86% | +$120K |
|
1014
Intellia Therapeutics
NTLA
$1.29B
| $259K | ﹤0.01% |
4,996
+2,724
| +120% | +$141K |
|
|
CBL
1015
CBL Properties
CBL
$990M
| $255K | ﹤0.01% |
10,839
| – | – |
|
1016
Vir Biotechnology
VIR
$732M
| $253K | ﹤0.01% |
9,943
-40
| -0.4% | -$1.02K |
|
1017
Ocugen
OCGN
$322M
| $251K | ﹤0.01% |
+110,672
| New | +$251K |
|
1018
Arrowhead Research
ARWR
$4.02B
| $250K | ﹤0.01% |
7,088
+2,769
| +64% | +$97.7K |
|
1019
Codexis
CDXS
$218M
| $248K | ﹤0.01% |
23,685
+15,202
| +179% | +$159K |
|
|
CIO
1020
City Office REIT
CIO
$280M
| $247K | ﹤0.01% |
19,045
| – | – |
|
|
BFS
1021
Saul Centers
BFS
$812M
| $245K | ﹤0.01% |
5,198
| – | – |
|
1022
Immersion
IMMR
$230M
| $244K | ﹤0.01% |
45,612
-43,858
| -49% | -$235K |
|
1023
Vontier
VNT
$6.37B
| $243K | ﹤0.01% |
10,560
| – | – |
|
1024
Xos
XOS
$20.3M
| $243K | ﹤0.01% |
+4,409
| New | +$243K |
|
1025
IDEAYA Biosciences
IDYA
$2.38B
| $238K | ﹤0.01% |
17,270
+6,854
| +66% | +$94.5K |
|